VS
Therapeutic Areas
Natco Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lenalidomide (Naxlen) | Multiple Myeloma, Myelodysplastic Syndromes | Approved |
| Sofosbuvir + Velpatasvir (Hepcvir-V) | Hepatitis C Virus (HCV) | Approved |
| Ledipasvir + Sofosbuvir | Hepatitis C Virus (HCV) | Approved |
| Tamoxifen | Breast Cancer | Approved |
| Capecitabine | Colorectal Cancer, Breast Cancer | Approved |
| Imatinib | Chronic Myeloid Leukemia (CML) | Approved |
| Olaparib | Ovarian Cancer, Breast Cancer (BRCA-mutated) | ANDA Filed |
| Lenalidomide (Revlimid Generic) | Multiple Myeloma | ANDA Filed |
Leadership Team at Natco Pharma
VN
V.C. Nannapaneni
Chairman & Managing Director
RN
Rajeev Nannapaneni
Vice Chairman & CEO
PB
P. Bhaskara Narayana
Chief Financial Officer
MA
M. Adinarayana
Company Secretary & Compliance Officer
DR
D. Rajkumar
Whole-time Director
DG
Dr. G. S. Prasad
Independent Director
MS
M. S. Mohan
Independent Director
PV
P. V. R. K. Prasad
Independent Director
DK
Dr. K. V. Subrahmanyam
Independent Director